Buy Stocks Easy | About Us
March 7, 2021
Buy Stocks Easy | Online Stocks

ZGNX


Buy Zogenix, Inc. Stock (symbol: ZGNX) Easy Online

Company Name: Zogenix, Inc.

Symbol: ZGNX

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2010

ZGNX Current Share Price

Today's ZGNX ( Zogenix, Inc. ) opening price: $

Yesterday's ZGNX ( Zogenix, Inc. ) closing price: $

Zogenix, Inc. Stock ( symbol: ZGNX ) Price Chart since IPO (2010):

12 Months Zogenix, Inc. Stock ( symbol: ZGNX ) Price Chart

Popular Questions about Zogenix, Inc. Public Stock ( ZGNX )

A: Zogenix, Inc. stock symbol (also called stock or share ticker) is ZGNX

A: Zogenix, Inc. IPO (Initial Public Offering) took place on 2010

A: Zogenix, Inc.'s stock (ZGNX symbol) price at ther IPO (initial Public Offering) was $

Q: Is ZGNX stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Zogenix, Inc. stock (symbol: ZGNX) at the beginning of 2019, at the opening share price of $43.7500, with a minimum of $200, by now your shares would be worth $1114 and your profit would be $914 - SHOW ONLY IF PROFIT.

Buy Zogenix, Inc. Stock Easy Online

Zogenix, Inc. Stock Ticker Price Chart since IPO:





Zogenix, Inc. Stock Price Yesterday



 


Zogenix, Inc. Stock Price – Last Week




 


Zogenix, Inc. Stock Price – Last Month




 


Zogenix, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            https://www.youtube.com/watch?v=OcOuQJOYtq4
                            

                                
Final Trades: Alibaba, Blackstone, Northern Trust & more

                                
                                
The "Halftime Report" traders give their top stocks to watch for th...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/02/1955072/0/en/JAMA-Neurology-Publishes-Phase-3-Study-of-Zogenix-Investigational-Drug-FINTEPLA-in-Dravet-Syndrome-Patients-Taking-Stiripentol-Containing-Antiepileptic-Drug-Regimens.html
                            

                                
JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

                                
                                
EMERYVILLE, Calif., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Zogenix, In...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/609220/zogenix-zgnx-reports-q3-loss-misses-revenue-estimates
                            

                                
Zogenix (ZGNX) Reports Q3 Loss, Misses Revenue Estimates

                                
                                
Zogenix (ZGNX) delivered earnings and revenue surprises of 9.52% an...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/25/1935704/0/en/Zogenix-Announces-New-Positive-Data-for-Its-Investigational-Drug-FINTEPLA-in-Dravet-Syndrome.html
                            

                                
Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA®  in Dravet Syndrome

                                
                                
EMERYVILLE, Calif., Oct.  25, 2019  (GLOBE NEWSWIRE) -- Zogenix, In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/21/1932487/0/en/Zogenix-Announces-Presentation-of-New-Data-for-FINTEPLA-for-the-Treatment-of-Dravet-Syndrome-at-the-Child-Neurology-Society-Annual-Meeting.html
                            

                                
Zogenix Announces Presentation of New Data for FINTEPLA® for the Treatment of Dravet Syndrome at the Child Neurology Society Annual Meeting

                                
                                
EMERYVILLE, Calif., Oct.  21, 2019  (GLOBE NEWSWIRE) -- Zogenix, In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/07/1925786/0/en/Zogenix-Presents-Positive-Clinical-Study-Results-for-Investigational-Treatment-for-TK2-Deficiency.html
                            

                                
Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency

                                
                                
EMERYVILLE, Calif., Oct.  07, 2019  (GLOBE NEWSWIRE) -- Zogenix, In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/26/1921144/0/en/Zogenix-Resubmits-New-Drug-Application-for-FINTEPLA-for-the-Treatment-of-Dravet-Syndrome-to-U-S-Food-and-Drug-Administration.html
                            

                                
Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

                                
                                
EMERYVILLE, Calif., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Zogenix, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/18/1961939/0/en/The-Lancet-Publishes-Phase-3-Trial-Results-for-Zogenix-Investigational-Drug-FINTEPLA-in-Dravet-Syndrome.html
                            

                                
The Lancet Publishes Phase 3 Trial Results for Zogenix  Investigational Drug FINTEPLA® in Dravet Syndrome

                                
                                
FINTEPLA as adjunctive therapy showed a significant, dose-dependent...


                            

                        
                    

                


                            

                    


                        
                            https://www.youtube.com/watch?v=OcOuQJOYtq4
                            

                                
Final Trades: Alibaba, Blackstone, Northern Trust & more

                                
                                
The "Halftime Report" traders give their top stocks to watch for th...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/02/1955072/0/en/JAMA-Neurology-Publishes-Phase-3-Study-of-Zogenix-Investigational-Drug-FINTEPLA-in-Dravet-Syndrome-Patients-Taking-Stiripentol-Containing-Antiepileptic-Drug-Regimens.html
                            

                                
JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

                                
                                
EMERYVILLE, Calif., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Zogenix, In...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/609220/zogenix-zgnx-reports-q3-loss-misses-revenue-estimates
                            

                                
Zogenix (ZGNX) Reports Q3 Loss, Misses Revenue Estimates

                                
                                
Zogenix (ZGNX) delivered earnings and revenue surprises of 9.52% an...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/25/1935704/0/en/Zogenix-Announces-New-Positive-Data-for-Its-Investigational-Drug-FINTEPLA-in-Dravet-Syndrome.html
                            

                                
Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA®  in Dravet Syndrome

                                
                                
EMERYVILLE, Calif., Oct.  25, 2019  (GLOBE NEWSWIRE) -- Zogenix, In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/21/1932487/0/en/Zogenix-Announces-Presentation-of-New-Data-for-FINTEPLA-for-the-Treatment-of-Dravet-Syndrome-at-the-Child-Neurology-Society-Annual-Meeting.html
                            

                                
Zogenix Announces Presentation of New Data for FINTEPLA® for the Treatment of Dravet Syndrome at the Child Neurology Society Annual Meeting

                                
                                
EMERYVILLE, Calif., Oct.  21, 2019  (GLOBE NEWSWIRE) -- Zogenix, In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/07/1925786/0/en/Zogenix-Presents-Positive-Clinical-Study-Results-for-Investigational-Treatment-for-TK2-Deficiency.html
                            

                                
Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency

                                
                                
EMERYVILLE, Calif., Oct.  07, 2019  (GLOBE NEWSWIRE) -- Zogenix, In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/26/1921144/0/en/Zogenix-Resubmits-New-Drug-Application-for-FINTEPLA-for-the-Treatment-of-Dravet-Syndrome-to-U-S-Food-and-Drug-Administration.html
                            

                                
Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

                                
                                
EMERYVILLE, Calif., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Zogenix, I...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.